Mrs. Wang has over 15 years of clinical development experience in the pharmaceutical industry. Prior to joining Kangpu, Mrs. Wang served in clinical development leadership roles at various well-known biotech and pharmaceutical companies including AstraZeneca, Allergan, Kyowa Kirin, Celgene and Amgen. She has successfully led more than fifteen global clinical studies (Apremilast, Zilovertamab, Cariprazine, Milnacipran, Istradefylline, and Ticagrelor) ranging from Phase I to Phase IV in immunology, oncology, neurology, psychiatry, and cardiology, and led and supported multiple successful NDA/sNDA filings including Otezla, Vraylar and Nourianz. Mrs. Wang received her Master of Medicine from Peking University Health Science Center (formerly Beijing Medical University) and Master of Science from University of Notre Dame in the United States.